Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing.
Hepatocelleular carcinoma (HCC)
Living Donor Liver Transplantation (LDLT)
Mutational signature
Whole exome sequencing
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
02
02
2024
accepted:
17
07
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Chronic hepatitis and liver cirrhosis lead to accumulation of genetic alterations driving HCC pathogenesis. This study is designed to explore genomic landscape of HCC in Egyptian patients by whole exome sequencing. Whole exome sequencing using Ion Torrent was done on 13 HCC patients, who underwent surgical intervention (7 patients underwent living donor liver transplantation (LDLT) and 6 patients had surgical resection}. Mutational signature was mostly S1, S5, S6, and S12 in HCC. Analysis of highly mutated genes in both HCC and Non-HCC revealed the presence of highly mutated genes in HCC (AHNAK2, MUC6, MUC16, TTN, ZNF17, FLG, MUC12, OBSCN, PDE4DIP, MUC5b, and HYDIN). Among the 26 significantly mutated HCC genes-identified across 10 genome sequencing studies-in addition to TCGA, APOB and RP1L1 showed the highest number of mutations in both HCC and Non-HCC tissues. Tier 1, Tier 2 variants in TCGA SMGs in HCC and Non-HCC (TP53, PIK3CA, CDKN2A, and BAP1). Cancer Genome Landscape analysis revealed Tier 1 and Tier 2 variants in HCC (MSH2) and in Non-HCC (KMT2D and ATM). For KEGG analysis, the significantly annotated clusters in HCC were Notch signaling, Wnt signaling, PI3K-AKT pathway, Hippo signaling, Apelin signaling, Hedgehog (Hh) signaling, and MAPK signaling, in addition to ECM-receptor interaction, focal adhesion, and calcium signaling. Tier 1 and Tier 2 variants KIT, KMT2D, NOTCH1, KMT2C, PIK3CA, KIT, SMARCA4, ATM, PTEN, MSH2, and PTCH1 were low frequency variants in both HCC and Non-HCC. Our results are in accordance with previous studies in HCC regarding highly mutated genes, TCGA and specifically enriched pathways in HCC. Analysis for clinical interpretation of variants revealed the presence of Tier 1 and Tier 2 variants that represent potential clinically actionable targets. The use of sequencing techniques to detect structural variants and novel techniques as single cell sequencing together with multiomics transcriptomics, metagenomics will integrate the molecular pathogenesis of HCC in Egyptian patients.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Chronic hepatitis and liver cirrhosis lead to accumulation of genetic alterations driving HCC pathogenesis. This study is designed to explore genomic landscape of HCC in Egyptian patients by whole exome sequencing.
METHODS
METHODS
Whole exome sequencing using Ion Torrent was done on 13 HCC patients, who underwent surgical intervention (7 patients underwent living donor liver transplantation (LDLT) and 6 patients had surgical resection}.
RESULTS
RESULTS
Mutational signature was mostly S1, S5, S6, and S12 in HCC. Analysis of highly mutated genes in both HCC and Non-HCC revealed the presence of highly mutated genes in HCC (AHNAK2, MUC6, MUC16, TTN, ZNF17, FLG, MUC12, OBSCN, PDE4DIP, MUC5b, and HYDIN). Among the 26 significantly mutated HCC genes-identified across 10 genome sequencing studies-in addition to TCGA, APOB and RP1L1 showed the highest number of mutations in both HCC and Non-HCC tissues. Tier 1, Tier 2 variants in TCGA SMGs in HCC and Non-HCC (TP53, PIK3CA, CDKN2A, and BAP1). Cancer Genome Landscape analysis revealed Tier 1 and Tier 2 variants in HCC (MSH2) and in Non-HCC (KMT2D and ATM). For KEGG analysis, the significantly annotated clusters in HCC were Notch signaling, Wnt signaling, PI3K-AKT pathway, Hippo signaling, Apelin signaling, Hedgehog (Hh) signaling, and MAPK signaling, in addition to ECM-receptor interaction, focal adhesion, and calcium signaling. Tier 1 and Tier 2 variants KIT, KMT2D, NOTCH1, KMT2C, PIK3CA, KIT, SMARCA4, ATM, PTEN, MSH2, and PTCH1 were low frequency variants in both HCC and Non-HCC.
CONCLUSION
CONCLUSIONS
Our results are in accordance with previous studies in HCC regarding highly mutated genes, TCGA and specifically enriched pathways in HCC. Analysis for clinical interpretation of variants revealed the presence of Tier 1 and Tier 2 variants that represent potential clinically actionable targets. The use of sequencing techniques to detect structural variants and novel techniques as single cell sequencing together with multiomics transcriptomics, metagenomics will integrate the molecular pathogenesis of HCC in Egyptian patients.
Identifiants
pubmed: 39123171
doi: 10.1186/s12920-024-01965-w
pii: 10.1186/s12920-024-01965-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Subventions
Organisme : Science and Technology Development Fund
ID : Basic and Applied Research Grant Call 7 (BARG Call 7, Project ID:38229).
Organisme : Science and Technology Development Fund
ID : Basic and Applied Research Grant Call 7 (BARG Call 7, Project ID:38229).
Organisme : Science and Technology Development Fund
ID : Basic and Applied Research Grant Call 7 (BARG Call 7, Project ID:38229).
Organisme : Science and Technology Development Fund
ID : Basic and Applied Research Grant Call 7 (BARG Call 7, Project ID:38229).
Organisme : Science and Technology Development Fund
ID : Basic and Applied Research Grant Call 7 (BARG Call 7, Project ID:38229).
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Elghazaly H, GabAllah A, Eldin NB. P-019 Clinic-pathological pattern of hepatocellular carcinoma (HCC) in Egypt. Ann Oncol. 2018;29. https://doi.org/10.1093/annonc/mdy151.018 .
Wang H, Zhou H, Li X, Wang P, Liu G, Liu W, et al. Detection of tumor- related biomarkers in hepatocellular carcinoma patients by sequencing circulating cell-free DNA. Clin Oncol. 2019;4:1645.
Maloberti T, De Leo A, Sanza V, Gruppioni E, Altimari A, Riefolo M, Visani M, Malvi D, D’Errico A, Tallini G, Vasuri F, de Biase D. Correlation of molecular alterations with pathological features in hepatocellular carcinoma: literature review and experience of an Italian center. World J Gastroenterol. 2022;28(25):2854–66.
doi: 10.3748/wjg.v28.i25.2854
pubmed: 35978866
pmcid: 9280731
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. J Hepatol. 2018;69(2):461–511.
doi: 10.1016/j.jhep.2018.03.026
Markou A, Tzanikou E, Lianidou E. The potential of liquid biopsy in the management of cancer patients. Semin Cancer Biol. 2022;84:69-79. https://doi.org/10.1016/j.semcancer.2022.03.013 .
Ganesamoorthy D, Robertson AJ, Chen W, Hall MB, Cao MD, Ferguson K, Coin LJ. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content. BMC Cancer. 2022;22(1):1–13.
doi: 10.1186/s12885-021-09160-1
Kunadirek P, Chuaypen N, Jenjaroenpun P, Wongsurawat T, Pinjaroen N, Sirichindakul P, Tangkijvanich P. Cell-free DNA analysis by whole-exome sequencing for hepatocellular carcinoma: a pilot study in Thailand. Cancers. 2021;13(9):2229.
doi: 10.3390/cancers13092229
pubmed: 34066484
pmcid: 8125351
Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020;72(2):215–29. https://doi.org/10.1016/j.jhep.2019.08.017 .
doi: 10.1016/j.jhep.2019.08.017
pubmed: 31954487
Imamura T, Okamura Y, Ohshima K, et al. Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. BMC Cancer. 2022;22:1046. https://doi.org/10.1186/s12885-022-10143-z .
doi: 10.1186/s12885-022-10143-z
pubmed: 36199046
pmcid: 9535898
Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet. 2014;59(1):5–15.
doi: 10.1038/jhg.2013.114
pubmed: 24196381
Botstein D, Risch N. (2003): Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet. 2003;33(Suppl):228–37.
doi: 10.1038/ng1090
pubmed: 12610532
Tetreault M, Bareke E, Nadaf J, Alirezaie N, Majewski J. Whole-exome sequencing as a diagnostic tool: current challenges and future opportunities. Expert Rev Mol Diagn. 2015;15(6):749–60.
doi: 10.1586/14737159.2015.1039516
pubmed: 25959410
Mazzaferro V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England J Med. 1996;334(11). https://doi.org/10.1056/nejm199603143341104 .
Yao FY et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6). https://doi.org/10.1053/jhep.2001.24563 .
Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. https://doi.org/10.1016/j.jhep.2019.09.026 . PMID: 31954493.
doi: 10.1016/j.jhep.2019.09.026
pubmed: 31954493
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C. Bruix J (2022): BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018 . Epub 2021 Nov 19 PMID: 34801630.
doi: 10.1016/j.jhep.2021.11.018
pubmed: 34801630
Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691-1700.e3 PMID: 24583061.
doi: 10.1053/j.gastro.2014.02.032
pubmed: 24583061
Lucena-Aguilar G, Sánchez-López AM, Barberán-Aceituno C, Carrillo-Ávila JA, López-Guerrero JA, Aguilar-Quesada R. DNA source selection for downstream applications based on DNA quality indicators analysis. Biopreserv Biobank. 2016;14(4):264–70. https://doi.org/10.1089/bio.2015.0064 . Epub 2016 May 9. PMID: 27158753; PMCID: PMC4991598.
Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly. 2012;6(2):80â “92. https://doi.org/10.4161/fly.19695 .
Lee J, Lee AJ, Lee JK, Park J, Kwon Y, Park S, Chun H, Ju YS, Hong D. Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for genomic, transcriptional and epigenomic signatures. Nucleic Acids Res. 2018;46(w1):W102–8. https://doi.org/10.1093/nar/gky406 .
Pagel KA, et al. Integrated informatics analysis of cancer-related variants. JCO Clinical Cancer Informatics. 2020;4:310–7.
doi: 10.1200/CCI.19.00132
pubmed: 32228266
Carter H, et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009;69:6660–7.
doi: 10.1158/0008-5472.CAN-09-1133
pubmed: 19654296
pmcid: 2763410
Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20(6):682.
doi: 10.1038/nm.3559
pubmed: 24836576
pmcid: 4048335
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.
doi: 10.1126/science.1235122
pubmed: 23539594
pmcid: 3749880
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002 . PMID: 27993330; PMCID: PMC5707196.
doi: 10.1016/j.jmoldx.2016.10.002
pubmed: 27993330
pmcid: 5707196
Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–21. https://doi.org/10.1093/nar/gkac194 .
doi: 10.1093/nar/gkac194
pubmed: 35325185
pmcid: 9252805
Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65(5):1031–42. https://doi.org/10.1016/j.jhep.2016.05.035 . Epub 2016 Jun 2 PMID: 27262756.
doi: 10.1016/j.jhep.2016.05.035
pubmed: 27262756
Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu; Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017;169(7):1327–1341.e23. https://doi.org/10.1016/j.cell.2017.05.046 . PMID: 28622513; PMCID: PMC5680778.
Rogers MF, Shihab H, Gaunt TR, Campbell C. CScape: a tool for predicting oncogenic single-point mutations in the cancer genome. Nature Scientific Rep. 2017. http://cscape.biocompute.org.uk/
Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011;12(10):683–91.
doi: 10.1038/nrg3051
pubmed: 21878961
Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem. 2015;61(1):64–71. https://doi.org/10.1373/clinchem.2014.223040 .
doi: 10.1373/clinchem.2014.223040
pubmed: 25421801
Alexandrov LB, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47:1402–7.
doi: 10.1038/ng.3441
pubmed: 26551669
pmcid: 4783858
Zhuravleva E, O’Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol. 2022;19:367–82. https://doi.org/10.1038/s41575-022-00587-w .
doi: 10.1038/s41575-022-00587-w
pubmed: 35273358
Bhagwate AV, Liu Y, Winham SJ, et al. Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples. BMC Genomics. 2019;20:689. https://doi.org/10.1186/s12864-019-6056-8 .
doi: 10.1186/s12864-019-6056-8
pubmed: 31477010
pmcid: 6720378
Xie C, Wu H, Pan T, Zheng X, Yang X, Zhang G, Lian Y, Lin J, Peng L. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY). 2021;10;13(6):8563–8587. https://doi.org/10.18632/aging.202670 . Epub 2021 Mar 10. PMID: 33714200; PMCID: PMC8034943.
Wang DW, Zheng HZ, Cha N, Zhang XJ, Zheng M, Chen MM, Tian LX. Down-regulation of AHNAK2 inhibits cell proliferation, migration and invasion through inactivating the MAPK pathway in lung adenocarcinoma. Technol Cancer Res Treat. 2020;19:1533033820957006. https://doi.org/10.1177/1533033820957006 . PMID: 33000678; PMCID: PMC7533926.
doi: 10.1177/1533033820957006
pubmed: 33000678
pmcid: 7533926
Liu B, Dong Z, Lu Y, Ma J, Ma Z, Wang H. Prognostic value of MUC16 mutation and its correlation with immunity in hepatocellular carcinoma patients. Evid Based Complement Alternat Med. 2022;3478861. https://doi.org/10.1155/2022/3478861 . PMID: 36034941; PMCID: PMC9410786.
Huang Y, Huang X, Zeng J, Lin J. Knockdown of MUC16 (CA125) enhances the migration and invasion of hepatocellular carcinoma cells. Front Oncol. 2021;11:667669. https://doi.org/10.3389/fonc.2021.667669 . PMID: 34150633; PMCID: PMC8208084.
doi: 10.3389/fonc.2021.667669
pubmed: 34150633
pmcid: 8208084
Shen J, Qi L, Zou Z, Du J, Kong W, Zhao L, Wei J, Lin L, Ren M, Liu B. Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases. Sci Rep. 2020;10(1):4435. https://doi.org/10.1038/s41598-020-61298-3 . PMID: 32157118; PMCID: PMC7064516.
doi: 10.1038/s41598-020-61298-3
pubmed: 32157118
pmcid: 7064516
Liu Z, Wang L, Guo C, Liu L, Jiao D, Sun Z, Wu K, Zhao Y, Han X. TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer. J Cell Mol Med. 2021;25(7):3239–3251. https://doi.org/10.1111/jcmm.16393 . Epub 2021 Feb 23. PMID: 33624434; PMCID.
Tsui YM, Chan LK, Ng IOL. Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. Br J Cancer. 2020;122:1428–40. https://doi.org/10.1038/s41416-020-0823-9 .
doi: 10.1038/s41416-020-0823-9
pubmed: 32231294
pmcid: 7217836
Seaby EG, Pengelly RJ, Ennis S. Exome sequencing explained: a practical guide to its clinical application. Brief Funct Genomics. 2016;15(5):374–84. https://doi.org/10.1093/bfgp/elv054 .
doi: 10.1093/bfgp/elv054
pubmed: 26654982
Feng W, Zhao S, Xue D, et al. Improving alignment accuracy on homopolymer regions for semiconductor-based sequencing technologies. BMC Genomics. 2016;17(Suppl 7):521. https://doi.org/10.1186/s12864-016-2894-9 .
doi: 10.1186/s12864-016-2894-9
pubmed: 27556417
pmcid: 5001236
Javanmard D, Najafi M, Babaei MR, et al. Investigation of CTNNB1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection. Infect Agents Cancer. 2020;15:37. https://doi.org/10.1186/s13027-020-00297-5 .
doi: 10.1186/s13027-020-00297-5
Shibata,. T. Genomic landscape of hepatocarcinogenesis. J Hum Genet. 2021;66:845–51. https://doi.org/10.1038/s10038-021-00928-8 .
doi: 10.1038/s10038-021-00928-8
pubmed: 33958712
Liang N, Yang T, Huang Q, et al. Mechanism of cancer stemness maintenance in human liver cancer. Cell Death Dis. 2022;13:394. https://doi.org/10.1038/s41419-022-04848-z .
doi: 10.1038/s41419-022-04848-z
pubmed: 35449193
pmcid: 9023565
Zhu X, Wang Z, Qiu X, Wang W, Bei C, Tan C, Qin L, Ren Y, Tan S. Rs2303428 of MSH2 is associated with hepatocellular carcinoma prognosis in a chinese population. DNA Cell Biol. 2018;37(7):634–641. https://doi.org/10.1089/dna.2018.4224 . Epub 2018 Jun 6. PMID: 29874113.
Geramoutsou C, Nikou S, Karavias D, Arbi M, Tavlas P, Tzelepi V, Lygerou Z, Maroulis I, Bravou V. (2022): Focal adhesion proteins in hepatocellular carcinoma: RSU1 a novel tumour suppressor with prognostic significance. Pathol Res Pract. 2022;235:153950. https://doi.org/10.1016/j.prp.2022.153950 . Epub 2022 May 23 PMID: 35642986.
doi: 10.1016/j.prp.2022.153950
pubmed: 35642986
Hernández-Oliveras A, Izquierdo-Torres E, Hernández-Martínez G, Zarain-Herzberg Á, Santiago-García J. Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma. J Cell Commun Signal. 2021;15(3):433–445. https://doi.org/10.1007/s12079-020-00597-w . Epub 2021 Jan 4. PMID: 33398721; PMCID: PMC8222487.
Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Biomedicines. 2021;9:1639. https://doi.org/10.3390/biomedicines9111639 .
doi: 10.3390/biomedicines9111639
pubmed: 34829868
pmcid: 8615614
Farzaneh Z, Vosough M, Agarwal T, et al. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int. 2021;21:208. https://doi.org/10.1186/s12935-021-01924-w .
doi: 10.1186/s12935-021-01924-w
pubmed: 33849569
pmcid: 8045321
Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13:165. https://doi.org/10.1186/s13045-020-00990-3 .
doi: 10.1186/s13045-020-00990-3
pubmed: 33276800
pmcid: 7716495
Liu Y, Wang X, Yang Y. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma. Clin Mol Hepatol. 2020;26(4):742–50. https://doi.org/10.3350/cmh.2020.0178 . PMID: 32981290; PMCID: PMC7641559.
doi: 10.3350/cmh.2020.0178
pubmed: 32981290
pmcid: 7641559
Shi H, Zou Y, Zhong W, et al. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149:15311–22. https://doi.org/10.1007/s00432-023-05272-2 .
doi: 10.1007/s00432-023-05272-2
pubmed: 37608027
Gao L, Zhang Z, Zhang P, Yu M, Yang T. Role of canonical Hedgehog signaling pathway in liver. Int J Biol Sci. 2018;14(12):1636. https://doi.org/10.7150/ijbs.28089 . PMID: 30416378; PMCID: PMC6216024.
Moon H, Ro SW. MAPK/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel). 2021;13(12):3026. https://doi.org/10.3390/cancers13123026 . PMID: 34204242; PMCID: PMC8234271.
doi: 10.3390/cancers13123026
pubmed: 34204242
Nicholas TJ, Cormier MJ, Huang X, Qiao Y, Marth GT, Quinlan AR. OncoGEMINI: software for investigating tumor variants from multiple biopsies with integrated cancer annotations. Genome Med. 2021;13(1):46. https://doi.org/10.1186/s13073-021-00854-6 . PMID: 33771218; PMCID: PMC7995589.
doi: 10.1186/s13073-021-00854-6
pubmed: 33771218
pmcid: 7995589